Stock Ratings / Health Care / SCYX / financials

VERU (43) GRDX (26) NSRX (36) ALDX (50) ⌘ Pro Terminal →

SCYNEXIS Inc. (SCYX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.86 -2.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

SCYNEXIS Inc. (SCYX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $38.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCYX)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SCYX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $140.1M

FY24

Rev $3.7M

FY25

Rev $20.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$20.6M	52%	-78%	-$8.6M	-$5.3M	-45%
FY 2024	$3.7M	52%	-80%	-$21.3M	-$24.0M	-45%
FY 2023	$140.1M	52%	51.9%	$67.0M	$60.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCYX)

✓Walkthrough of SCYX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SCYX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.12%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.78H $3.88L $3.67C $3.86VOL 117.8K

RES: $5.06SUP: $3.54SMA50: $4.56SMA200: $5.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCYX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCYX Butterfly Map → + Track SCYX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCYX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCYX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SCYX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCYX)

Health Care Rank #849 of 1016 ⚔️ VERU vs SCYX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCYX vs. VERU, GRDX, NSRX, ALDX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SCYNEXIS Inc. (SCYX) ranks #849 by composite RQD confidence (34/100, grade E) and #779 by equity capitalization ($38.4M). Within this direct 5-issuer industry benchmark cohort, SCYX leads on earnings valuation at N/A trailing P/E, while GRDX leads on capital efficiency and profitability with -20.0% ROIC and -30.0% gross margin. ALDX currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with SCYX at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SCYX ACTIVE SCYNEXIS Inc.	E	34/100	—	—	-35.0%	-2.28%	$38.4M	Benchmark Subject
VERU Veru Inc.	D-	43/100	—	—	-35.0%	-1.76%	$38.0M	/veru-vs-scyx →
GRDX GridAI Technologies Corp.	E	26/100	—	-30.0%	-20.0%	-5.38%	$38.9M	/grdx-vs-scyx →
NSRX Nasus Pharma Ltd.	D-	36/100	—	—	-35.0%	-4.49%	$37.4M	/nsrx-vs-scyx →
ALDX Aldeyra Therapeutics Inc.	D	50/100	—	—	-35.0%	-3.58%	$39.8M	/aldx-vs-scyx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001178253

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SCYNEXIS Inc. (SCYX) reported GAAP revenue of $20.6M (+449.9% vs. FY2024 revenue of $3.7M , and -85.3% cumulative change since FY2023) , GAAP net income of -$8.6M, operating cash flow of -$5.3M, and free cash flow of -$5.3M (+78.0% YoY). On the balance sheet, SCYX closed FY2025 with $59.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$20.6M	-$8.6M	-$5.3M	-$5.3M	$59.0M	—
FY2024 (FY)	2024-12-31	$3.7M	-$21.3M	-$24.0M	-$24.0M	$90.6M	—
FY2023 (FY)	2023-12-31	$140.1M	$67.0M	$60.2M	$60.2M	—	—

3. SCYX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SCYNEXIS Inc. (NASDAQ: SCYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.86 (-2.28% 1D, market cap $38.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SCYX ranks #849 in composite RQD confidence.

How does SCYX compare to VERU and GRDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCYX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VERU (Veru Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $38.0M) and GRDX (GridAI Technologies Corp.) posts a E grade (26/100 RQD, P/E N/A, ROIC -20.0%, cap $38.9M). Among the 5-stock peer group, SCYX leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCYX?

Per SCYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001178253), SCYNEXIS Inc. generated $20.6M in revenue (+449.9% YoY), -$8.6M in net income, and -$5.3M in free cash flow against $59.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCYX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCYX last traded at $3.86 (-2.28% on volume of 133,511 shares), positioning the stock -15.35% below its 50-day simple moving average ($4.56) and -30.32% below its 200-day simple moving average ($5.54). Across its 52-week range of $3.53 to $9.12, SCYX sits at the 5.9% percentile with a 14-day RSI of 37.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.38 to $4.34).